ERBB2 and breast carcinoma: According to the recommendations of the International Ki67 in Breast Cancer Working Group, the validity of Ki67 immunohistochemistry as a prognostic marker in the clinical practice of breast cancer has been verified, especially for the identification of oestrogen receptor‐positive and HER2‐negative patients who do not need neoadjuvant therapy.6